ID   WM1799
AC   CVCL_A341
SY   WM-1799; WM 1799
DR   ArrayExpress; E-MTAB-2770
DR   Cosmic; 888851
DR   Cosmic; 1155560
DR   Cosmic; 1303067
DR   GEO; GSM109032
DR   GEO; GSM186477
DR   GEO; GSM186478
DR   GEO; GSM887736
DR   GEO; GSM888831
DR   Wikidata; Q54994197
RX   PubMed=15009714;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=22460905;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (Wistar).
CC   Sequence variation: Hemizygous for PTEN deletion (Wistar).
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.37%; Native American=0%; East Asian, North=4.29%; East Asian, South=0%; South Asian=2.08%; European, North=47.56%; European, South=45.7% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X->X,Y.
ST   Source(s): Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 13,16
ST   D19S433: 16,16.2
ST   D21S11: 30
ST   D2S1338: 18
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 9
ST   D8S1179: 12,14
ST   FGA: 19,24
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 24-05-19; Version: 15
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).